{"id":10105,"date":"2022-11-23T07:00:00","date_gmt":"2022-11-23T06:00:00","guid":{"rendered":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/"},"modified":"2022-11-23T07:00:00","modified_gmt":"2022-11-23T06:00:00","slug":"irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022","status":"publish","type":"mfn_news","link":"https:\/\/irlab.se\/sv\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/","title":{"rendered":"IRLAB deltar p\u00e5 SEB Annual Healthcare Summit den 23 november 2022"},"content":{"rendered":"

[mfn_before_post]<\/p>\n

\n

G\u00f6teborg, Sverige, 23 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att Richard Godfrey, VD p\u00e5 IRLAB, deltar p\u00e5 SEB Annual Healthcare Summit onsdagen den 23 november 2022.<\/strong><\/p>\n<\/div>\n

\n

Richard Godfrey, VD, deltar i en fr\u00e5gestund \u2019fireside chat\u2019 p\u00e5 onsdagen den 23 november 2022 kl. 11:20 som modereras av Dr. Christopher Uhde, senior aktieanalytiker f\u00f6r l\u00e4kemedels- och biotechbolag p\u00e5 SEB. Eventet s\u00e4nds live p\u00e5 https:\/\/seb.evitbe.com\/HealthcareSeminar<\/a>.
\u00a0
En inspelning av presentationen kommer att g\u00f6ras tillg\u00e4nglig p\u00e5 bolagets webbplats, www.irlab.se<\/a>, efter eventet.<\/p>\n<\/div>\n

\n

F\u00f6r mer information:<\/strong><\/p>\n

\n

Richard Godfrey, VD
Telefon: +46 730 70 69 00
E-mail:\u00a0richard.godfrey@irlab.se<\/a><\/p>\n<\/div>\n

\n

Om IRLAB<\/strong><\/p>\n

\n

IRLAB uppt\u00e4cker och utvecklar nya l\u00e4kemedel f\u00f6r behandling av Parkinsons sjukdom och andra sjukdomar i hj\u00e4rnan. Bolagets l\u00e4ngst framskridna l\u00e4kemedelskandidater, mesdopetam (IRL790) och pirepemat (IRL752) \u00e4r b\u00e5da i Fas IIb och \u00e4r designade f\u00f6r att behandla n\u00e5gra av de sv\u00e5raste symtomen relaterade till Parkinson. \u00c5r 2021 f\u00f6rv\u00e4rvade Ipsen, ett specialty pharma-bolag, de exklusiva globala r\u00e4ttigheterna till utveckling och kommersialisering av mesdopetam.
\u00a0
IRLAB har genererat alla sina l\u00e4kemedelskandidater och forts\u00e4tter att uppt\u00e4cka innovativa l\u00e4kemedelskandidater f\u00f6r behandling av neurologiska sjukdomar genom den egenutvecklade forskningsplattformen ISP (Integrative Screening Process). F\u00f6rutom IRLAB:s starka kliniska pipeline driver bolaget tv\u00e5 prekliniska program, IRL942 och IRL757, mot Fas I-studier. IRLAB \u00e4r noterat p\u00e5 Nasdaq Stockholm. Mer information p\u00e5\u00a0www.irlab.se.<\/a><\/p>\n<\/div>\n

\n

Bifogade filer<\/strong><\/p>\n

\n

IRLAB deltar p\u00e5 SEB Annual Healthcare Summit den 23 november 2022<\/a><\/p>\n<\/div>\n

[mfn_after_post]<\/p>\n","protected":false},"excerpt":{"rendered":"

G\u00f6teborg, Sverige, 23 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att Richard Godfrey, VD p\u00e5 IRLAB, deltar p\u00e5 SEB Annual Healthcare Summit onsdagen den 23 november 2022.<\/p>\n","protected":false},"template":"","class_list":["post-10105","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nIRLAB deltar p\u00e5 SEB Annual Healthcare Summit den 23 november 2022 - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IRLAB deltar p\u00e5 SEB Annual Healthcare Summit den 23 november 2022 - IRLAB\" \/>\n<meta property=\"og:description\" content=\"G\u00f6teborg, Sverige, 23 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att Richard Godfrey, VD p\u00e5 IRLAB, deltar p\u00e5 SEB Annual Healthcare Summit onsdagen den 23 november 2022.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/\",\"url\":\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/\",\"name\":\"IRLAB deltar p\u00e5 SEB Annual Healthcare Summit den 23 november 2022 - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2022-11-23T06:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\/\/irlab.se\/sv\/pressmeddelanden\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"IRLAB deltar p\u00e5 SEB Annual Healthcare Summit den 23 november 2022\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson's disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IRLAB deltar p\u00e5 SEB Annual Healthcare Summit den 23 november 2022 - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/","og_locale":"sv_SE","og_type":"article","og_title":"IRLAB deltar p\u00e5 SEB Annual Healthcare Summit den 23 november 2022 - IRLAB","og_description":"G\u00f6teborg, Sverige, 23 november 2022 \u2013 IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), ett biofarmaceutiskt bolag som uppt\u00e4cker och utvecklar nya behandlingar f\u00f6r de mest besv\u00e4rliga symtomen vid Parkinsons sjukdom, meddelade idag att Richard Godfrey, VD p\u00e5 IRLAB, deltar p\u00e5 SEB Annual Healthcare Summit onsdagen den 23 november 2022.","og_url":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/","og_site_name":"IRLAB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/","url":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/","name":"IRLAB deltar p\u00e5 SEB Annual Healthcare Summit den 23 november 2022 - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2022-11-23T06:00:00+00:00","breadcrumb":{"@id":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/mfn_news\/irlab-deltar-pa-seb-annual-healthcare-summit-den-23-november-2022\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/irlab.se\/sv\/pressmeddelanden\/"},{"@type":"ListItem","position":3,"name":"IRLAB deltar p\u00e5 SEB Annual Healthcare Summit den 23 november 2022"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson's disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news\/10105","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=10105"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}